U.S. stocks movement: Kodiak Sciences surged on October 1st due to DAYBREAK double milestone, director share purchase, and ophthalmology drug news

Kodiak Sciences October 1st Rally Analysis

Keywords: DAYBREAK dual endpoints, director increasing holdings, ophthalmic drugs

1. On September 28, the company announced that both Zenkuda and tabirafusp-tedKSI-501 achieved their primary endpoints in the Phase 3 DAYBREAK trial for wet age-related macular degeneration; Zenkuda demonstrated non-inferior visual gains compared to aflibercept, with a primary endpoint p-value of 0.0007.

2. On September 28, Zenkuda showed rapid retinal drying and sustained efficacy. Under strict retreatment standards, 54% of patients achieved a six-month dosing interval after one year. The company plans to submit a biologics license application for Zenkuda in the fourth quarter of 2026.

3. On September 28, Kodiak Sciences director Baker Bros. Advisors LP increased its holdings by purchasing 1.2262 million ordinary shares at an average price of $76.3265 per share, with a transaction value of approximately $93.5888 million. The company focuses on drug development for retinal diseases, advancing late-stage clinical projects using an antibody biopolymer conjugate platform.

(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)